Volpi R, Coiro V, Salvi M, Pelosi G, Mancini P, Chiodera P
J Endocrinol Invest. 1983 Apr;6(2):101-5. doi: 10.1007/BF03350580.
Growth hormone (GH) secretory response to metoclopramide (MCP) administration was evaluated in 9 male patients with liver cirrhosis and in 6 normal controls. As expected, MCP did not modify serum GH concentrations in normal subjects. In contrast, a striking GH secretory response to MCP was observed in 5 out of 9 cirrhotics. In the other four patients serum GH levels did not show any variation after MCP. The different behavior between cirrhotic "responders" and "non responders" can not be interpreted on the basis of the medical history or the clinical and laboratory data. Three hypothesis are proposed: i) The effect of MCP could be promoted by estrogens and inhibited by androgens. ii) False neurochemical transmitters could affect dopaminergic system of some cirrhotics, allowing or inhibiting the GH response to MCP. iii) MCP could stimulate GH secretion by a serotonergic mechanism. These findings provide further evidence of a modification of the GH secretory pattern in patients with cirrhosis of the liver.
对9名男性肝硬化患者和6名正常对照者给予胃复安（MCP）后，评估其生长激素（GH）分泌反应。正如预期的那样，MCP并未改变正常受试者的血清GH浓度。相反，9名肝硬化患者中有5名对MCP出现了显著的GH分泌反应。在其他4名患者中，MCP后血清GH水平未显示任何变化。肝硬化“反应者”和“无反应者”之间的不同表现无法根据病史或临床及实验室数据来解释。提出了三种假设：i）MCP的作用可能受雌激素促进，受雄激素抑制。ii）假性神经化学递质可能影响某些肝硬化患者的多巴胺能系统，从而允许或抑制GH对MCP的反应。iii）MCP可能通过5-羟色胺能机制刺激GH分泌。这些发现为肝硬化患者GH分泌模式的改变提供了进一步的证据。
